[1]李 丽,蒋芙蓉,赵丽英,等.血清肿瘤坏死因子受体相关因子3和卵泡抑素样蛋白1检测对系统性红斑狼疮患者吗替麦考酚酯治疗无效的预测价值[J].陕西医学杂志,2024,(9):1254-1258.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.022]
　LI Li,JIANG Furong,ZHAO Liying,et al.Predictive value of serum TRAF3 and FSTL1 levels in patients with systemic lupus erythematosus for failure to respond to mycophenolate mofetil treatment[J].,2024,(9):1254-1258.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.022]
点击复制

血清肿瘤坏死因子受体相关因子3和卵泡抑素样蛋白1检测对系统性红斑狼疮患者吗替麦考酚酯治疗无效的预测价值
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年9期
页码:
1254-1258
栏目:
临床检验
出版日期:
2024-09-05

文章信息/Info

Title:
Predictive value of serum TRAF3 and FSTL1 levels in patients with systemic lupus erythematosus for failure to respond to mycophenolate mofetil treatment
作者:
李 丽1; 蒋芙蓉1; 赵丽英1; 方先英2
(1.川北医学院附属三台医院内分泌科,四川 绵阳 621100; 2.德阳市旌阳区中医院内分泌科,四川 德阳 618099)
Author(s):
LI Li; JIANG Furong; ZHAO Liying; FANG Xianying
(Department of Endocrinology,Santai Hospital Affiliated to North Sichuan Medical College,Mianyang 621100,China)
关键词:
系统性红斑狼疮;  肿瘤坏死因子受体相关因子3;  卵泡抑素样蛋白1;  吗替麦考酚酯;  预测价值
Keywords:
Systemic lupus erythematosus;  Tumor necrosis factor receptor-associated factor 3;  Follistatin-like protein 1;  Mycophenolate mofetil;  Predictive value
分类号:
R 593.241
DOI:
DOI:10.3969/j.issn.1000-7377.2024.09.022
文献标志码:
A
摘要:
目的:分析血清肿瘤坏死因子受体相关因子3(TRAF3)和卵泡抑素样蛋白1(FSTL1)水平检测对系统性红斑狼疮患者吗替麦考酚酯治疗无效的预测价值。方法:选择系统性红斑狼疮患者58例为研究对象,采用吗替麦考酚酯治疗,根据治疗效果分为有效组(45例)和无效组(13例)。检测血清TRAF3、FSTL1水平,分析TRAF3、FSTL1与系统性红斑狼疮患者吗替麦考酚酯治疗效果的关系,以及血清TRAF3、FSTL1对系统性红斑狼疮患者吗替麦考酚酯治疗无效的预测价值。结果:系统性红斑狼疮患者经吗替麦考酚酯治疗后,血清TRAF3、FSTL1水平降低(均P<0.05)。与无效组比较,有效组血清TRAF3、FSTL1水平降低(均P<0.05)。Logistic回归分析结果显示,TRAF3、FSTL1是系统性红斑狼疮患者吗替麦考酚酯治疗效果的影响因素(均P<0.05)。ROC曲线分析显示,血清TRAF3、FSTL1对系统性红斑狼疮患者吗替麦考酚酯治疗无效具有一定的预测价值,且联合检测预测价值更高(均P<0.05)。结论:血清TRAF3、FSTL1高表达与系统性红斑狼疮患者吗替麦考酚酯治疗无效相关,两者联合检测能提升系统性红斑狼疮患者治疗无效风险的预测价值。
Abstract:
Objective:To analyze the predictive value of serum tumor necrosis factor receptor-associated factor 3(TRAF3)and follistatin-like protein 1(FSTL1)levels for failure to respond to mycophenolate mofetil in patients with systemic lupus erythematosus(SLE).Methods:A total of 58 patients with SLE were selected as the study subjects,and were treated with mycophenolate mofetil.According to the treatment effect,they were divided into effective group(45 cases)and ineffective group(13 cases).The serum levels of TRAF3 and FSTL1 were detected,and the relationship between TRAF3,FSTL1 and the efficacy of mycophenolate mofetil in patients with SLE was analyzed.The predictive value of serum TRAF3 and FSTL1 for failure to respond to mycophenolate mofetil in patients with SLE was analyzed.Results:The levels of TRAF3 and FSTL1 were decreased in SLE patients after mycophenolate mofetil treatment(both P<0.05).Compared with the ineffective group,the serum levels of TRAF3 and FSTL1 in the effective group were decreased(all P<0.05).Logistic regression analysis showed that TRAF3 and FSTL1 were the influencing factors of the therapeutic effect of mycophenolate mofetil in SLE patients(all P<0.05).ROC curve analysis showed that serum TRAF3 and FSTL1 had a certain predictive value for the failure of mycophenolate mofetil treatment in SLE patients,and the predictive value of combined detection was higher(all P<0.05).Conclusion:The high expression of TRAF3 and FSTL1 is associated with no response to mycophenolate mofetil treatment in SLE patients,and the combined detection of TRAF3 and FSTL1 can improve the predictive value of no response to mycophenolate mofetil treatment in SLE patients.Overexpression of serum TRAF 3 and FSTL 1 is associated with ineffective treatment with malcocohenol lipid in patients with systemic lupus erythematosus and can be used as a key biological indicator to predict therapeutic failure in patients with systemic lupus erythematosus.

参考文献/References:

[1] ZUCCHII D,ELEFANTE E,CALABRES E,et al.One year in review 2019:Systemic lupus erythematosus[J].Clin Exp Rheumatol,2019,37(5):715-722.
[2] MYRPHY L.Systemic lupus erythematosus:Overview,management and COVID-19[J].Br J Nurs,2022,31(7):348-355.
[3] GRASSO E A,CACCIATIRE M,GENTILE C,et al.Epilepsy in systemic lupus erythematosus[J].Clin Exp Rheumatol,2021,39(3):651-659.
[4] 杨帆,沈俊逸,林彤彤,等.清瘟败毒饮联合糖皮质激素、环磷酰胺治疗系统性红斑狼疮气营热盛证临床研究[J].陕西中医,2020,41(9):1197-1199,1204.
[5] USATINE R P,HEATHH C R.Systemic lupus erythematosus[J].J Fam Pract,2023,72(5):e1-e2.
[6] DERDULSKA J M,RUDNICKA L,SZYKUT-BADACZEWSKA A,et al.Neonatal lupus erythematosus-practical guidelines[J].J Perinat Med,2021,49(5):529-538.
[7] 李春霄,赖江,郝平生,等.三黄固本汤对激素干预下SLE小鼠骨密度、骨矿含量及脂代谢的影响[J].陕西中医,2021,42(10):1354-1357.
[8] AZAR A,ALDAOUD N,HARDENBERGH D,et al.Systemic lupus erythematosus and common variable immunodeficiency[J].J Clin Rheumatol,2022,28(1):e245-e248.
[9] 林千祺,许夏雨,邢诒喜,等.贝利尤单抗联合吗替麦考酚酯治疗系统性红斑狼疮临床研究[J].中国药业,2023,32(2):86-89.
[10] 吕昌伟,张静涛,郗海涛,等.银杏素促进成纤维样滑膜细胞中TRAF3蛋白的表达缓解类风湿关节炎[J].中国骨质疏松杂志,2022,28(2):178-184.
[11] WANG S,LIU Z G.Inhibition of microRNA-143-3p attenuates cerebral ischemia/reperfusion injury by targeting FSTL1[J].Neuromolecular Medicine,2021,23(4):500-510.
[12] 中华医学会风湿病学分会,国家皮肤与免疫疾病临床医学研究中心,中国系统性红斑狼疮研究协作组.2020中国系统性红斑狼疮诊疗指南[J].中华内科杂志,2020,59(3):172-185.
[13] SUNDARAM T G,MUHAMMED H,GUPTA L,et al.Catatonia in systemic lupus erythematosus:Case based review[J].Rheumatol Int,2022,42(8):1461-1476.
[14] 张彦平,贺军涛,殷鉴,等.尿液免疫球蛋白轻链检测对系统性红斑狼疮肾脏损伤的诊断价值[J].陕西医学杂志,2020,49(9):1172-1174.
[15] 韦佩祺,苏梓健,梁芳,等.microRNA在系统性红斑狼疮中的作用机制研究进展[J].陕西医学杂志,2023,52(2):238-240,封3.
[16] 杨西超,冯媛,吴振彪,等.系统性红斑狼疮患者血尿酸水平变化临床研究[J].陕西医学杂志,2019,48(7):906-908.
[17] POLIC A,OBICAN S G.Pregnancy in systemic lupus erythematosus[J].Birth Defects Res,2020,112(15):1115-1125.
[18] CANN M P,SAGE A M,MCKINNON E,et al.Childhood systemic lupus erythematosus:Presentation,management and long-term outcomes in an Australian cohort[J].Lupus,2022,31(2):246-255.
[19] 张凌霄,李婷,许羚,等.贝利木单抗治疗系统性红斑狼疮的模型化疗效评价[J].中国临床药理学与治疗学,2021,26(2):174-181.
[20] 庞杰.系统性红斑狼疮患者血清学指标水平与病情严重程度的关系[J].现代医学与健康研究:电子版,2023,7(4):113-115.
[21] 黄荣军,文静,高静琳,等.系统性红斑狼疮患者并发中重度血小板减少症的疗效观察及相关因素分析[J].实用医学杂志,2017,33(10):1619-1622.
[22] 朱禹潼,张晓楠,关溪,等.脱氢胆酸调控OPG/RANK和TRAF3抑制破骨细胞分化[J].中国骨质疏松杂志,2024,30(1):12-16.
[23] 汤茜,宋冬明,王方明,等.系统性红斑狼疮患者血清TRAF3、miR-107表达水平及与疾病活动度的关系[J].国际检验医学杂志,2023,44(21):2607-2611.
[24] 盖楠楠,张薇,华莎.不同病程系统性红斑狼疮患者血清PGRN、FSTL1水平及临床意义分析[J].贵州医药,2021,45(2):224-225.
[25] 吕松林.不同病程系统性红斑狼疮患者血清PGRN、FSTL1水平及临床意义[J].河南医学研究,2019,28(20):3770-3771.

相似文献/References:

[1]李 赟.系统性红斑狼疮患者血清补体C5a和红细胞沉降率检测及临床意义[J].陕西医学杂志,2020,49(1):52.
　LI Yun..Expression of serum C5a and ESR in patients with systemic lupus erythematosus and its clinical significance[J].,2020,49(9):52.
[2]张彦平,贺军涛△,殷 鉴,等.尿液免疫球蛋白轻链检测对系统性红斑狼疮肾脏损伤的诊断价值*[J].陕西医学杂志,2020,49(9):1172.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.030]
　ZHANG Yanping,HE Juntao,YIN Jian,et al.Diagnostic value of urine U-kap and U-lam detection in renalinjury of systemic lupus erythematosus[J].,2020,49(9):1172.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.030]
[3]付永涛,王莉平,郭金明,等.羟氯喹通过Toll样受体4/核因子-κB信号通路对系统性红斑狼疮小鼠肺损伤的影响[J].陕西医学杂志,2023,52(11):1483.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.007]
　FU Yongtao,WANG Liping,GUO Jinming,et al.Effect of hydroxychloroquine on lung injury in mice with systemic lupus erythematosus via TLR4/NF-κB signaling pathway[J].,2023,52(9):1483.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.007]
[4]王赓丰,崔家康,孟庆良.铁死亡在系统性红斑狼疮中的作用研究进展[J].陕西医学杂志,2024,(5):710.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.031]
　WANG Gengfeng,CUI Jiakang,MENG Qingliang.Research progress on the role of ferrosis in systemic lupus erythematosus[J].,2024,(9):710.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.031]
[5]王玲玲,詹宇威,杨 舟.系统性红斑狼疮合并感染患者淋巴细胞亚群、PLR、NLR、MLR水平变化及检测意义[J].陕西医学杂志,2024,(11):1487.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.010]

备注/Memo

备注/Memo:
基金项目:四川省中医药管理局科学技术研究专项课题(2023MS239)
更新日期/Last Update: 2024-09-04